Oncimmune Reports Substantial Growth in their Interim Results & Alan Green on 3 Companies
On today's podcast: Oncimmune Reports Substantial Growth in their Interim Results & Alan Green on 3 Companies
Dr Adam M Hill, CEO of Oncimmune #ONC discusses the highlights from their interim results in which they report, substantial revenue growth with increased commercial activity across the business.
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
Alan Green, CEO of Brand Communications talks about:
(Interview starts 12 minutes 40 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.